BioCentury
ARTICLE | Clinical News

Celecoxib/amlodipine besylate: Phase III data

December 21, 2015 8:00 AM UTC

A double-blind, placebo-controlled, U.K. Phase IlI trial in 152 patients with hypertension showed that once-daily oral 200 mg celecoxib/10 mg amlodipine besylate for 2 weeks met the primary endpoint o...